Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$2.09 USD

2.09
1,644,474

+0.06 (2.96%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $2.09 0.00 (0.00%) 5:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates

by Zacks Equity Research

Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.

Omnicell (OMCL) Lags Q4 Earnings Estimates, Beats on Revenues

by Zacks Equity Research

Omnicell (OMCL) fourth-quarter 2019 results reflect strong segmental performances.

Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4

by Zacks Equity Research

Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.

Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.

Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.

ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss

by Zacks Equity Research

Flagship Impella drives ABIOMED's (ABMD) fiscal third-quarter results; FY20 revenue guidance slashed.

Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q2

by Zacks Equity Research

We are upbeat about Cardiovascular Systems' (CSII) year-over-year uptick in global Coronary and peripheral device revenues during Q2.

Haemonetics (HAE) Q3 Earnings & Revenues Beat, Margins Expand

by Zacks Equity Research

Haemonetics (HAE) fiscal third-quarter 2020 results reflect strong performances in Plasma and Hospital segments.

Boston Scientific (BSX) Q4 Earnings Beat, Margins Decline

by Zacks Equity Research

Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

QIAGEN (QGEN) registered revenue growth across majority of its geographies and each of its operating segments in Q4

Cerner (CERN) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Cerner (CERN) fourth-quarter results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.

Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow

by Zacks Equity Research

Zimmer Biomet (ZBH) benefits from strong sales growth across all geographies as well as segmental strengths at CER.

Phibro (PAHC) Q2 Earnings Top Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Phibro (PAHC) witnessed revenue decline in two of its core segments and contraction in operating margin in Q2.

McKesson (MCK) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

McKesson's (MCK) fiscal third-quarter results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty Solutions, Medical-Surgical Solutions and Other segments.

Accuray (ARAY) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Accuray (ARAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Company News for Jan 30, 2020

by Zacks Equity Research

Companies In The News Are: ARAY, MTSI, CVLT, XLNX

Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall

by Zacks Equity Research

Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.

Accuray (ARAY) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 114.29% and 0.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Up 10.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intuitive Surgical (ISRG) Boosts da Vinci System With FDA Nod

by Zacks Equity Research

Intuitive Surgical (ISRG) is likely to strengthen its da Vinci surgical system with the recent FDA nod.

Accuray (ARAY) Q1 Wider Than Expected, FY20 View Retained

by Zacks Equity Research

Accuray (ARAY) reiterates revenue and adjusted EBITDA view for fiscal 2020.

Accuray (ARAY) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of -10.00% and -4.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics Boosts VIT Product Portfolio With New Buyout

by Zacks Equity Research

AngioDynamics (ANGO) is likely to see an expansion of its already existing VIT product portfolio with the buyout of Eximo Medical.

Luminex Gets FDA Nod for ARIES MRSA Assay, Boosts Platform

by Zacks Equity Research

Luminex (LMNX) receives FDA clearance for the ARIES MRSA assay, which is likely to provide a boost to the company's ARIES platform.